---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000007"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-03-19T23:59:59+00:00"
generated_at: "2026-05-15T09:43:25.858310+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports FY2025 net loss $140.1M; cash $124.2M plus $75M debt draw

## Summary
- Net loss FY2025: $140.1M ($9.04/share), vs FY2024 net income $1.7B from 101 Transaction gain.
- Cash $124.2M at Dec 31, 2025; received $75M gross proceeds from Oxford Finance on Mar 18, 2026.
- R&D expense $113M (down 44% YoY); G&A $23.3M (down 82% YoY) due to lower clinical costs and prior-year transaction expenses.
- ozekibart BLA submission for chondrosarcoma expected early Q2 2026; PFS data for CRC expansion Q2 2026.
- INBRX-106: interim ORR data from Phase 2/3 HNSCC trial expected Q2 2026; PFS data at ESMO Q4 2026.

## SEC filing metadata
- accession: 0002007919-26-000007
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-03-19T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/0002007919-26-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/inhibrx-20260319.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000007
- JSON: https://secwatch.observer/filing/0002007919-26-000007.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000007.txt

## Key facts
- Earnings Releases
  Inhibrx Biosciences, Inc. reported the fourth quarter and fiscal year 2025 results: net income Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1.
  - Period: the fourth quarter and fiscal year 2025
  - Net income: Net loss was $32.8 million during the fourth quarter of 2025, or $2.11 per share, basic and diluted; Net loss was $140.1
  - Result: reported results
  source text: Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/0002007919-26-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.